In a phase 1 study, the first of these selective BRAF inhibitors, vemurafenib, demonstrated substantial tumor regression in 81% of patients with metastatic melanoma who had a BRAF (V600E) mutation and received the recommended phase 2 dose [13,14]. Here, BRAF is linked to neoplasm.